The FDA’s nod for suzetrigine bolsters confidence in the pharmaceutical industry’s strategy to target sodium channels.
The prescribing information for Qelbree (viloxazine extended-release capsules) has been updated with new pharmacodynamic and lactation data.
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback